Sophia Frentzas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sophia Frentzas has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Adnan Nagrial
The University of Sydney, Sydney, Australia
15 shared publications - Agata A. Bielska
AstraZeneca, Waltham, USA
15 shared publications - Andrew L. Coveler
Fred Hutchinson Cancer Center Seattle Washington USA
15 shared publications - Anne M. Noonan
Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, USA, USA
15 shared publications - Christos Fountzilas
Department of Medicine Roswell Park Comprehensive Cancer Center Buffalo New York USA
15 shared publications - David R. Spigel
Sarah Cannon Research Institute, Nashville, TN
15 shared publications
Latest Publications
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Exploratory overall survival analysis of oleclumab + durvalumab + GnP (Arm A3) versus GnP alone (Arm A1) by IHC or ctDNA-based biomarkers per all patients (A) or CD73 high only population (B)
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Exploratory overall survival analysis of oleclumab + durvalumab + GnP (Arm A3) versus GnP alone (Arm A1) by IHC or ctDNA-based biomarkers per all patients (A) or CD73 high only population (B)
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Table 3 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Efficacy in the dose-expansion phase (intent-to-treat population; N = 170).
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Efficacy in the dose-expansion phase (intent-to-treat population; N = 170).
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Figure 2 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
A, PFS and (B) OS in the dose-expansion phase overall (ITT) population; (C) PFS and (D) OS in patients with low CD73 levels, and (E) PFS and (F) OS in patients with high CD73 levels. ITT, intent-to-treat; NC, not calculable.
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
A, PFS and (B) OS in the dose-expansion phase overall (ITT) population; (C) PFS and (D) OS in patients with low CD73 levels, and (E) PFS and (F) OS in patients with high CD73 levels. ITT, intent-to-treat; NC, not calculable.
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Figure 1 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
CONSORT diagram for the dose-expansion phase. “a” denotes arm A1: death (n = 1); withdrawal by patient (n = 8); other (n = 4). Arm A3: death (n = 1); withdrawal by patient (n = 2); other (n = 2). “b” denotes patients could be counted more than once in this category if they discontinued different chemotherapy options for different reasons. “c” denotes as permitted per study protocol, patients from arms A2 and A3 continued to receive immunotherapy off-study after the study closure on July 22, 2022, and patients from all arms continued to receive treatment per standard of care at their site. “d” denotes end of study status as defined in the protocol. “e” denotes “sponsor decision" and includes patients either still on treatment or in survival follow-up at the time of study closure. N, number of patients in each treatment group.
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
CONSORT diagram for the dose-expansion phase. “a” denotes arm A1: death (n = 1); withdrawal by patient (n = 8); other (n = 4). Arm A3: death (n = 1); withdrawal by patient (n = 2); other (n = 2). “b” denotes patients could be counted more than once in this category if they discontinued different chemotherapy options for different reasons. “c” denotes as permitted per study protocol, patients from arms A2 and A3 continued to receive immunotherapy off-study after the study closure on July 22, 2022, and patients from all arms continued to receive treatment per standard of care at their site. “d” denotes end of study status as defined in the protocol. “e” denotes “sponsor decision" and includes patients either still on treatment or in survival follow-up at the time of study closure. N, number of patients in each treatment group.
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Study design: dose-escalation and dose-expansion phases
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Study design: dose-escalation and dose-expansion phases
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Baseline median variant allelic frequency (VAF) by KRAS status (A), exploratory OS and PFS stratified by baseline median VAF (B) and distribution of KRAS mutation status (C), VAF (D) and blood TMB (E) by arm
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Baseline median variant allelic frequency (VAF) by KRAS status (A), exploratory OS and PFS stratified by baseline median VAF (B) and distribution of KRAS mutation status (C), VAF (D) and blood TMB (E) by arm
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Table 1 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Patient demographics and disease characteristics in the dose-expansion phase (intent-to-treat population; N = 170).
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Patient demographics and disease characteristics in the dose-expansion phase (intent-to-treat population; N = 170).
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Table 2 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
TEAEs occurring at any severity in ≥20% of patients in any arm in the dose-expansion phase (as-treated population; N = 170).
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
TEAEs occurring at any severity in ≥20% of patients in any arm in the dose-expansion phase (as-treated population; N = 170).